Decoy Therapeutics (NASDAQ:DCOY) Trading Up 2.9% – Here’s Why

Shares of Decoy Therapeutics (NASDAQ:DCOY) rose 2.9% on Wednesday . The stock traded as high as $6.02 and last traded at $6.01. Approximately 11,496 shares traded hands during trading, a decline of 7% from the average daily volume of 12,385 shares. The stock had previously closed at $5.84.

Analysts Set New Price Targets

DCOY has been the subject of several research analyst reports. Wall Street Zen raised shares of Decoy Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 21st. LADENBURG THALM/SH SH initiated coverage on shares of Decoy Therapeutics in a research note on Friday, January 23rd. They set a “buy” rating and a $30.00 target price for the company. Finally, Weiss Ratings lowered shares of Decoy Therapeutics from a “sell (e+)” rating to a “sell (e)” rating in a research note on Wednesday, April 22nd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $30.00.

Decoy Therapeutics Trading Up 2.9%

The company has a market cap of $3.19 million, a price-to-earnings ratio of -0.01 and a beta of 0.38. The firm has a 50-day moving average of $6.78.

Decoy Therapeutics (NASDAQ:DCOY) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $43.10 earnings per share for the quarter. On average, research analysts expect that Decoy Therapeutics will post -12.97 EPS for the current year.

Decoy Therapeutics Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577.